Tarceva® (erlotinib) in advanced non-small cell lung cancer

[Guest guest]

Hi Hugo & All,

 

See: http://tinyurl.com/2qytr5

 

> BASEL, SWITZERLAND -- July 15, 2005 -- Treatment with the innovative

> cancer drug Tarceva® (erlotinib) in patients with advanced non-small

> cell lung cancer (NSCLC) resulted in significantly longer survival

> compared to placebo (42.5% improvement), according to a landmark study

> published in the New England Journal of Medicine (NEJM). Tarceva is an

> oral, once-daily therapy from a novel class of anti-cancer drugs known

> as 'EGFR inhibitors' (epidermal growth factor receptor inhibitors) and

> it is the first EGFR inhibitor to have demonstrated a survival benefit

> in cancer.

>

> Lung Governs the Skin, right? A small note on the technicalities: the

> term " epidermal " in this case is referring to the early bioassay. EGF

> is active on a wide variety of cell types, but /is/ especially active

> on epithelial (skin, or " surface " ) cells. Hugo

 

Best regards,